CLNNNasdaq

Clene Inc.

Consumer Defensive·Neurology·Phase 2·Salt Lake City, UT, United States
NeurologyImmunologyInfectious Disease

Clene Inc. (CLNN): 5 pipeline candidates · ~5 mo cash runway · 5 clinical trials. Updated within the last hour.

5.2/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway1.5

5.4 months

Financial Health10.0

D/E -2.15 · 0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

N/A

Insider Signal0.0

1 buy · 49 sells (180d)

A transparent, data-derived signal for Clene Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$75.8M

Cash

$6.0M

Quarterly Burn

$4.5M

Runway

5.4 mo

Revenue

$15K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Nov 2026
Today~7 mo out
Catalyst within runway

Pipeline (5 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

25

Total value held

$6.3M

HolderSharesValue
vanguard capital management llc616,460$3.0M
scoggin management lp300,000$1.5M
geode capital management, llc95,874$473K
peak6 llc50,012$247K
vanguard fiduciary trust co43,715$216K
parsons capital management inc/ri37,243$184K
blackrock, inc.33,799$167K
state street corp29,801$147K
morgan stanley19,832$98K
northern trust corp16,143$80K

Showing top 10 of 25 institutional holders of Clene Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

5 clinical trials·1 FDA decision·CEO: Mr. Robert Etherington MBA

Frequently asked questions

How many drug candidates are in Clene Inc.'s pipeline?

Clene Inc. (CLNN) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Clene Inc.'s lead drug candidate?

Clene Inc.'s most advanced tracked candidate is cnm-agzn17 (Preclinical) for Infectious diseases and wound/burn healing.

What is Clene Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Clene Inc. has approximately 5.4 months of cash runway.

What is Clene Inc.'s market capitalization?

Clene Inc.'s market capitalization is approximately $75.8M.

Who is the CEO of Clene Inc.?

Mr. Robert Etherington MBA is the chief executive officer of Clene Inc. (CLNN).

Get the full picture on Clene Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.